Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arno Therapeutics names new CFO
Mr Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and mergers and acquisition activities. Prior to joining
Mr Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and mergers and acquisition activities. Prior to joining
The financing was led by GE Asset Management (on behalf of the General Electric Pension Trust), with participation by Cross Creek Capital (a Wasatch Advisors company) and Integral
Fred Hassan, chairman and CEO of Schering-Plough, said: The actions announced today are part of Schering-Plough’s long-term global geographic expansion strategy. Investing in the Asia-Pacific Region, and especially
Clearance under the Hart-Scott-Rodino Act meets one of the conditions to the tender offer. The offer is scheduled to expire on September 2, 2008 unless extended. The offer
Services include regulatory submissions, project management and field monitoring. Revenue recognition will begin in the current quarter with the remainder expected to occur on a proportional performance basis
The company said that the data reported indicate that MDRNA’s dicer substrate small interfering RNAs (siRNAs) are highly active against multiple strains of influenza A virus including seasonal
However, the special committee would consider a proposal that recognizes the value of the company and reflects the significant benefits that would accrue to Roche as a result
It is reported that PMX-60056 represents an entirely new class of drug, which PolyMedix calls a heptagonist, and is reportedly the only reversing agent for heparin and the
MEDI-545 is a fully human antibody generated by Medarex’s UltiMAb Human Antibody Development System. Under the terms of the agreement, Medarex will receive a milestone payment of an
In April 2008, ImClone announced the establishment of an agreement with the FDA under a special protocol assessment for this trial. The SPA is a written agreement between